Capabilities by Region: United Kingdom
Greenhill has considerable advisory experience in the United Kingdom. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a vast network of corporate relationships throughout the United Kingdom.
Greenhill established its presence in the United Kingdom in January 1998 with the opening of a London office.
For more information on Greenhill’s advisory practice in the United Kingdom and our capabilities in the region, please contact President David Wyles or Head of U.K. M&A Dean Rodrigues in our London Office.
Below we highlight a few of the transactions on which we have advised in this region:
Recent Transactions
Sort By
Bruc Energy, one of the largest renewable energy platforms in Spain with c.4 GWp of Solar PV assets under operation, construction and development
Advising Bruc OPT Energy Partners (“BROP”), a renewable energy JV owned by OPTrust and Mr. Juan Béjar, on the sale of a 50% stake in Bruc Energy, one of the largest renewable energy platforms in Spain with c.4 GWp of Solar PV assets under operation, construction and development, to funds managed by Universities Superannuation Scheme (“USS”), the largest pension scheme by assets in the UK
Equity investment in NuScale Power LLC
Advised Fluor Corporation, a global engineering, procurement and construction company and the majority investor in NuScale, a leading developer of small modular reactor nuclear technology, on the equity capital raise for NuScale
Speedcast International Limited
Advised the Ad Hoc Group of First Lien Lenders on the Chapter 11 restructuring of Speedcast International Limited (ASX:SDA)
Acacia Pharma Group plc
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
Biogix, Inc.
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc